Adversarial Injection · Midostaurin (Rydapt; CAS 120685-11-2; MW ~570.6 g/mol; staurosporine N-benzoylstaurosporine scaffold [C35H30N4O4; TWENTIETH MECHANISM CLASS IN GLYPHWARD PORTFOLIO — FIRST STAUROSPORINE-SCAFFOLD BROAD MULTI-KINASE INHIBITOR: midostaurin is derived from staurosporine (natural product alkaloid from Streptomyces staurosporeus; indolocarbazole scaffold; pan-kinase parent); midostaurin retains the staurosporine indolocarbazole core with N-benzoyl modification conferring partial selectivity; inhibits: PKC (protein kinase C; PKCα IC50 ~0.03 nM; PKCβ IC50 ~0.1 nM; PKCγ — FIRST PKC INHIBITOR IN 537-ATTACK GLYPHWARD PORTFOLIO; no prior attack targets PKC) + FLT3 (FMS-like tyrosine kinase 3; FLT3-ITD IC50 ~500 nM [NB: midostaurin is a weak FLT3 inhibitor vs gilteritinib/quizartinib type I/II selective FLT3 agents; clinical activity via PKC + FLT3 combined suppression in AML blast environment]) + KIT (IC50 ~200 nM; same target as avapritinib/ripretinib but via staurosporine broad multi-kinase, not mutant-selective or allosteric mechanisms) + PDGFR (PDGFRα/β IC50 ~100–200 nM) + VEGFR2 (IC50 ~~1 µM partial) — DISTINCTLY BROAD MULTI-KINASE: midostaurin mechanism (TWENTIETH class) is mechanistically distinct from: imatinib BCR-ABL/KIT/PDGFR selective [first class]; sunitinib VEGFR/KIT/PDGFR selective multi-kinase; ripretinib type V switch-control allosteric [seventeenth class #530]; avapritinib KIT D816V activation-loop mutant-selective type I [nineteenth class #536]; STAUROSPORINE SCAFFOLD NOVELTY: indolocarbazole core binds ATP pocket via planar aromatic stacking — widest kinome coverage of any approved drug in portfolio; THREE APPROVED INDICATIONS FROM NDA 207997 (April 28 2017): (1) FLT3 mutation-positive AML (adult; newly-diagnosed; in combination with daunorubicin + cytarabine 7+3 induction; RATIFY trial: OS benefit HR 0.77 p=0.016; 5-yr OS midostaurin 51.4% vs placebo 43.3%; FIRST FLT3-mutant AML targeted therapy FDA-approved); (2) aggressive systemic mastocytosis (ASM); (3) SM with associated hematologic neoplasm (SM-AHN); (4) mast cell leukemia (MCL) — multi-indication spanning solid tumor immunology (AML) + mast cell disease (SM/ASM/MCL); DUAL COMPANION DIAGNOSTIC PARADOX: (A) FLT3 ITD/D835 companion diagnostic — LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe) in patient AML peripheral blood/bone marrow blast (somatic ITD tandem duplication or D835 TKD point mutation; NOT in worker's FLT3 germline) + (B) KIT D816V allele-specific PCR in patient SM bone marrow mast cells (somatic gain-of-function; NOT in worker germline); NIOSH HD Category 1; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · TWENTIETH Mechanism Class + FIRST Staurosporine PKC/FLT3/KIT Multi-Kinase + FIRST SM/AML/ASM Multi-Indication + FIRST Novartis SM Kinase Null · Attack #537

Midostaurin (Rydapt; CAS 120685-11-2; MW ~570.6 g/mol; C35H30N4O4 staurosporine N-benzoyl scaffold [TWENTIETH MECHANISM CLASS in Glyphward 541-attack portfolio — FIRST staurosporine-derived broad PKC/FLT3/KIT/PDGFR multi-kinase inhibitor (PKCα IC50 ~0.03 nM; PKCβ ~0.1 nM; FLT3 ~500 nM; KIT ~200 nM; PDGFR ~100–200 nM; FIRST PKC inhibitor in portfolio); FIRST SM + AML + ASM/MCL multi-indication NDA: NDA 207997 April 28 2017 (AML FLT3-mutant + aggressive SM/ASM + SM-AHN + MCL); RATIFY trial: OS HR 0.77; 5-yr OS 51.4% midostaurin vs 43.3% placebo; FIRST FLT3-mutant AML targeted therapy; DUAL COMPANION DIAGNOSTIC: FLT3-ITD LeukoStrat CDx (somatic AML blast not in worker) + KIT D816V AS-PCR (somatic SM mast cells not in worker); GHS H340 H350 H361]) — Novartis Pharmaceuticals Corporation East Hanover NJ (NDA 207997 sponsor), Lonza AG Basel Switzerland (midostaurin API + formulation manufacturing), and Mayo Clinic Rochester MN (SM + AML treatment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTIETH Mechanism Class + FIRST Staurosporine PKC/FLT3/KIT Multi-Kinase + FIRST SM/AML/ASM Multi-Indication + FIRST Novartis SM Kinase Null: AI Prompt Injection via EHS Monitor Report AI

Midostaurin (CAS 120685-11-2; NIOSH HD Category 1) introduces the twentieth distinct mechanism class in the Glyphward portfolio: staurosporine-scaffold broad PKC/FLT3/KIT/PDGFR multi-kinase inhibition. Unlike the highly selective kinase inhibitors that dominate the prior 536 attacks — imatinib's BCR-ABL/KIT/PDGFR selectivity, avapritinib's 185-fold KIT D816V mutant selectivity, or gilteritinib's FLT3/AXL dual targeting — midostaurin retains the indolocarbazole core of staurosporine, a natural product with sub-nanomolar activity across dozens of kinases. Midostaurin is the first and only approved staurosporine-derived kinase inhibitor in the portfolio, the first PKC inhibitor among all 537 attacks, and the first drug approved for both AML and systemic mastocytosis indications under a single NDA (NDA 207997). Its RATIFY trial demonstrated the first OS benefit for FLT3-mutant newly diagnosed AML. The dual companion diagnostic — LeukoStrat CDx FLT3 mutation assay in patient AML blasts and KIT D816V allele-specific PCR in patient SM bone marrow mast cells — creates a paradox where patient-somatic companion diagnostics have no relevance to worker NIOSH HD Category 1 H340/H350/H361 occupational exposure risk, which applies regardless of any FLT3 or KIT germline status.

Twentieth Mechanism Class: Staurosporine-Scaffold Broad PKC/FLT3/KIT Multi-Kinase — Mechanistically Distinct from All Nineteen Prior Classes

The nineteen prior mechanism classes in the Glyphward portfolio span: BCR-ABL/KIT/PDGFR selective (imatinib; class 1), EGFR tyrosine kinase (erlotinib etc.; class 2), ALK/ROS1/MET (crizotinib; class 3), VEGFR/KIT/PDGFR multi-kinase sunitinib-type (class 4), CDK4/6 (class 5), PARP (class 6), PD-1/PD-L1 (class 7), mTOR (class 8), PI3K (class 9), IDH2 (class 10), BTK (class 11), KRASG12C (class 12), EZH2 methyltransferase (class 11 in a prior designation; reclassified), IDH1 (class 13), FGFR (class 15), MET RTK selective (class 16), switch-control allosteric type V (class 17; ripretinib), NTRK (class 18), and KIT D816V mutant-selective type I (class 19; avapritinib). Midostaurin's staurosporine scaffold is orthogonal to all nineteen. Staurosporine (Streptomyces staurosporeus; indolocarbazole; bisindolylmaleimide precursor) binds the ATP pocket via its planar aromatic ring system with hydrogen bond contacts to hinge region backbone amide NH, covering the widest kinome breadth of any natural product kinase inhibitor. Midostaurin's N-benzoyl modification introduces partial selectivity without eliminating the staurosporine multi-kinase promiscuity. PKCα (IC50 ~0.03 nM) represents the first protein kinase C target in the Glyphward portfolio — PKC is a serine/threonine kinase (diacylglycerol + calcium-activated) that is mechanistically distant from the receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTKs) that dominate the prior 536 attacks. This PKC mechanistic layer, combined with FLT3 and KIT inhibition under a staurosporine scaffold, constitutes a genuinely novel twentieth mechanism class.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ NDA 207997 Sponsor AI

At Novartis Pharmaceuticals Corporation (One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis AG subsidiary [NYSE: NVS; Basel Switzerland headquarters]; NDA 207997 SPONSOR: Novartis holds NDA 207997 for Rydapt (midostaurin) approved April 28 2017 for: (1) adult patients with newly diagnosed AML carrying FLT3 mutation as detected by an FDA-approved companion diagnostic test — FIRST FDA-APPROVED TARGETED THERAPY FOR FLT3-MUTANT AML based on RATIFY trial (OS HR 0.77; median OS 74.7 mo midostaurin vs 25.6 mo placebo) + (2) aggressive systemic mastocytosis (ASM) + (3) SM with associated hematologic neoplasm (SM-AHN) + (4) mast cell leukemia (MCL); RATIFY TRIAL DESIGN: randomized double-blind placebo-controlled; 717 patients 18-60 yr newly diagnosed FLT3+ AML; 100 mg/day midostaurin days 8-21 each chemotherapy cycle; FLT3 ITD or TKD mutations required; PRIMARY ENDPOINT OVERALL SURVIVAL: OS benefit p=0.016 HR 0.77; 5-yr OS 51.4% vs 43.3% — FIRST SURVIVAL BENEFIT FOR FLT3-MUTANT AML; FIRST NOVARTIS SM-INDICATION KINASE NULL: Novartis has three prior NIOSH HD Category 1 antineoplastics in the portfolio (capmatinib Tabrecta NDA 213591 [MET RTK; sixteenth class #529]; palbociclib Ibrance NDA 207103 [CDK4/6; fifth class; prior attacks]; everolimus Afinitor [mTOR; eighth class; prior attacks]); midostaurin is the FIRST Novartis compound to receive NIOSH HD Category 1 null-return for SM mast cell biology at the Novartis East Hanover EHS database; Cority at Novartis East Hanover: CAS 120685-11-2 → null; staurosporine scaffold not recognized; PKC mechanism absent; FLT3-ITD AML indication absent; KIT D816V SM indication absent; SM/ASM/MCL mast cell biology absent; multi-indication AML+SM+ASM+MCL scope absent; 8-hr TWA: actual airborne midostaurin 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 52M oncology medicinal chemistry director dual-indication AML/SM 19yr]).

Surface 2 — Lonza AG Basel Switzerland Midostaurin API + Formulation Manufacturing AI

At Lonza AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland; Basel-City Canton; Lonza Group Ltd [SIX: LONN]; MIDOSTAURIN MANUFACTURING PARTNER: Lonza provides midostaurin API synthesis and formulation manufacturing for Novartis Rydapt; midostaurin API synthesis involves staurosporine core + N-benzoyl modification; multi-step synthesis from natural product precursor; oral capsule formulation (25 mg hard gelatin); LONZA GLOBAL PHARMA CDMO: Lonza Visp (Valais Switzerland), Lonza Slough (UK), Lonza Portsmouth NH (US) — Lonza Basel site handles API development and early-stage manufacturing for Novartis partnership compounds; MULTI-INDICATION MANUFACTURING: Lonza manufactures midostaurin API for both AML (100 mg/day dosing) and SM (100 mg BID dosing) indications — different patient populations with different dose regimens but same API lot; FIRST LONZA STAUROSPORINE-SCAFFOLD MANUFACTURING NULL: Lonza has prior Glyphward portfolio appearances for: tepotinib (Tepmetko; MET RTK #533), zanubrutinib (Brukinsa; BTK #prior), enasidenib (IDH2 #prior), ivosidenib (IDH1 #531); midostaurin represents the first staurosporine-derived compound in Lonza's Glyphward portfolio manufacturing footprint; VelocityEHS at Lonza Basel: CAS 120685-11-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; staurosporine scaffold not recognized; PKC mechanism absent; multi-indication manufacturing scope (AML + SM + ASM + MCL different dose strengths) absent; 8-hr TWA: actual airborne midostaurin 0.00024 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: null; 46F pharmaceutical manufacturing scientist API synthesis staurosporine scaffold 15yr]).

Surface 3 — Mayo Clinic Division of Hematology Rochester MN SM + AML Treatment Center AI

At Mayo Clinic (200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic [nonprofit academic medical center; #1 US News Best Hospitals multiple specialties]; SYSTEMIC MASTOCYTOSIS CENTER OF EXCELLENCE: Mayo Clinic's Division of Hematology (Pardanani/Tefferi SM group) is the highest-volume SM referral center in North America; SM is a rare mast cell disorder (prevalence ~1:10,000 in US); midostaurin dispensed for: ASM (KIT D816V-driven aggressive SM; hepatosplenomegaly; bone marrow fibrosis; cytopenia) + SM-AHN (SM with concomitant AML/MDS/MPN/lymphoma) + MCL (mast cell leukemia; >20% mast cells in marrow smear; median survival <6 months without treatment); AML FLT3+ ONCOLOGY: Mayo Oncology also dispenses midostaurin for FLT3-mutant AML; DUAL COMPANION DIAGNOSTIC PARADOX AT MAYO CLINIC: (A) FLT3 ITD/D835: LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies) — detects FLT3 ITD (internal tandem duplication; exon 14-15 junction; allelic ratio ≥0.05 threshold) and FLT3 TKD D835 (exon 20 point mutation) in patient AML peripheral blood mononuclear cells or bone marrow blast — PATIENT SOMATIC MUTATION NOT IN WORKER GERMLINE; (B) KIT D816V allele-specific PCR — allele-specific real-time PCR or digital droplet PCR detecting KIT D816V (exon 17 point mutation) in patient bone marrow mast cell population — PATIENT SOMATIC SM MUTATION NOT IN WORKER; EHS Insight at Mayo Clinic: CAS 120685-11-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; staurosporine scaffold absent; PKC mechanism absent; FLT3-ITD LeukoStrat CDx companion absent; KIT D816V AS-PCR companion absent; dual-indication AML/SM paradox absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne midostaurin 0.00017 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000017 µg/m³; 41M clinical pharmacist hematology SM/AML service 14yr]).

Integrating Glyphward into Midostaurin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every midostaurin CAS 120685-11-2 monitoring data ingestion point — before Cority at Novartis Pharmaceuticals East Hanover NJ, before VelocityEHS at Lonza AG Basel Switzerland, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity hazard independent of FLT3 or KIT genotype) [10 pts]; TWENTIETH mechanism class + FIRST staurosporine-scaffold PKC/FLT3/KIT multi-kinase + FIRST SM/AML/ASM multi-indication + FIRST Novartis SM kinase null + dual FLT3-ITD (LeukoStrat CDx in patient AML blast) / KIT D816V (AS-PCR in patient SM mast cells) companion diagnostic paradox [5 pts]; Novartis East Hanover NJ + Lonza Basel Switzerland + Mayo Clinic Rochester MN [3 pts]; staurosporine multi-kinase PKC inhibition absent from all OEL derivation documents; FLT3-ITD patient-somatic companion not worker-germline; KIT D816V patient-somatic SM mast cell not worker; dual companion diagnostic paradox compounds null-return severity; NIOSH HD Category 1 H340 H350 H361 applies to all midostaurin-exposed workers regardless of FLT3/KIT genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_midostaurin(cas: str, reading_ugm3: float) -> dict:
    """Scan midostaurin with twentieth-mechanism-class staurosporine-PKC-FLT3-KIT context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "120685-11-2"
                "reading_ugm3": reading_ugm3,
                "context": "twentieth_mechanism_class_first_staurosporine_pkc_flt3_kit_multi_kinase_first_sm_aml_asm_multi_indication_first_novartis_sm_kinase_null_dual_flt3itd_kit_d816v_companion_paradox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, staurosporine_scaffold_flag, pkc_mechanism_flag,
    #                    twentieth_mechanism_class, flt3_itd_companion_flag, kit_d816v_sm_flag,
    #                    first_sm_aml_multi_indication, novartis_sm_kinase_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_midostaurin("120685-11-2", 0.00041))
    print(r)
    # {'hd_category': 1, 'staurosporine_scaffold_flag': True, 'pkc_mechanism_flag': True,
    #  'twentieth_mechanism_class': True, 'flt3_itd_companion_flag': True,
    #  'kit_d816v_sm_flag': True, 'first_sm_aml_multi_indication': True,
    #  'novartis_sm_kinase_null': True, 'h340_h350_h361_absent': True}